\-\ Texto\\:\\ \ \(0\)\
\-\ none\\ available\ \(6\)\
\-\ no\\ treatments\\ have\\ been\\ found\\ that\\ slow\\ the\\ progression\\ of\\ cyst\\ development\\ in\\ adpkd\\.\\ treatments\\ target\\ associated\\ complications\\,\\ such\\ as\\ antihypertensive\\ therapy\\ \\(ace\\ inhibitors\\ or\\ arbs\\)\\ for\\ elevated\\ blood\\ pressure\\,\\ slowing\\ development\\ of\\ left\\ ventricular\\ hypertrophy\\,\\ and\\ preserving\\ renal\\ function\\,\\(1\\)\\ and\\ identification\\ and\\ treatment\\ of\\ possible\\ uti\\ and\\ nephrolithiasis\\.\\ follow\\-up\\ includes\\ us\\ of\\ the\\ kidneys\\ every\\ 1\\-2\\ years\\.\\(2\\)\ \(0\)\
\-\ \\‚\\Ä\\¢\\ ct\\ stone\\ protocol\\:\\ numerous\\ liver\\ and\\ bilateral\\ renal\\ cysts\\ of\\ varying\\ sizes\\ and\\ small\\ renal\\ calcifications\\.\\ \ \(0\)\
\-\ \\‚\\Ä\\¢\\ mra\\ head\\ without\\ contrast\\:\\ unremarkable\\ \\-\\ no\\ aneurysms\ \(0\)\
\-\ adpkd\\ \\-autosomal\\ dominant\\ polycystic\\ kidney\\ disease\ \(0\)\
\-\ \\‚\\Ä\\¢\\ lymphoma\\ of\\ kidney\ \(0\)\
\-\ \\‚\\Ä\\¢\\ renal\\ cell\\ carcinoma\\ \ \(0\)\
\-\ \\‚\\Ä\\¢\\ tuberous\\ sclerosis\ \(1\)\
\-\ \\‚\\Ä\\¢\\ von\\ hippel\\-lindau\\ syndrome\ \(0\)\
\-\ \\‚\\Ä\\¢\\ multilocular\\ cystic\\ nephroma\ \(0\)\
\-\ \\‚\\Ä\\¢\\ echinococcosis\ \(0\)\
\-\ 44\\ y\\.o\\.\\ woman\\ with\\ abdominal\\ pain\ \(1\)\
\-\ adpkd\\ is\\ a\\ genetic\\ disorder\\ defined\\ by\\ growth\\ of\\ multiple\\ renal\\ cysts\\ that\\ result\\ in\\ kidney\\ destruction\\ and\\ renal\\ failure\\.\\ the\\ hereditary\\ abnormality\\ is\\ a\\ defect\\ in\\ one\\ of\\ two\\ genes\\:\\ polycystin\\ 1\\ pkd1\\)\\ and\\ \\ polycystin\\ 2\\ \\(pkd2\\)\\,\\ which\\ are\\ thought\\ to\\ be\\ important\\ in\\ cell\\-cell\\ and\\ cell\\-matrix\\ interactions\\ involved\\ in\\ tubular\\ epithelial\\ cell\\ growth\\.\\(3\\)\ \(0\)\
\-\ renal\\ manifestations\\ of\\ adpkd\ \(0\)\
\-\ adpkd\\ manifests\\ as\\ progressive\\ renal\\ failure\\ secondary\\ to\\ cyst\\ enlargement\\.\\ volume\\ progression\\ in\\ polycystic\\ kidney\\ disease\\ has\\ been\\ evaluated\\ in\\ a\\ recent\\ study\\ that\\ measured\\ the\\ correlation\\ between\\ mean\\ total\\ kidney\\ volume\\ and\\ cyst\\ volumes\\ as\\ measured\\ by\\ mri\\ over\\ a\\ three\\-year\\ period\\ and\\ iothalamate\\ clearance\\ as\\ a\\ measure\\ of\\ kidney\\ function\\.\\ the\\ study\\ found\\ that\\ a\\ baseline\\ total\\ kidney\\ volume\\ greater\\ than\\ 1500\\ ml\\ is\\ a\\ predictor\\ of\\ declining\\ glomerular\\ filtration\\ rate\\.\\ furthermore\\,\\ growth\\ of\\ kidney\\ size\\ occurs\\ at\\ the\\ same\\ rate\\ bilaterally\\,\\ and\\ is\\ directly\\ proportional\\ to\\ growth\\ of\\ cysts\\.\\(4\\)\\ \\ \ \(0\)\
\-\ renal\\ complications\\ include\\ hypertension\\,\\ uti\\,\\ defects\\ in\\ concentrating\\ ability\\,\\ hematuria\\,\\ nephrolithiasis\\,\\ and\\ possible\\ renal\\ cell\\ carcinoma\\.\\ flank\\ or\\ abdominal\\ pain\\ is\\ possible\\ and\\ can\\ be\\ due\\ to\\ infection\\,\\ nephrolithiasis\\,\\ cyst\\ hemorrhage\\ or\\ torsion\\,\\ and\\ associated\\ liver\\ complications\\ of\\ polycystic\\ liver\\ enlargement\\.\\ \\ proteinuria\\ is\\ not\\ a\\ major\\ feature\\ of\\ adpkd\\.\\ renal\\ cell\\ carcinoma\\ does\\ not\\ occur\\ at\\ increased\\ frequency\\ from\\ that\\ in\\ the\\ general\\ population\\,\\ but\\ is\\ more\\ likely\\ to\\ present\\ with\\ fever\\ and\\ bilateral\\ tumor\\.\\(5\\)\\ \ \(0\)\
\-\ extrarenal\\ manifestations\ \(0\)\
\-\ extrarenal\\ manifestations\\ of\\ adpkd\\ include\\ cerebral\\ aneurysms\\,\\ hepatic\\ cysts\\,\\ cardiac\\ valve\\ disease\\,\\ colonic\\ diverticula\\,\\ and\\ abdominal\\ wall\\ and\\ inguinal\\ hernias\\.\ \(0\)\
\-\ cerebral\\ aneurysms\\ are\\ the\\ most\\ serious\\ complication\\,\\ though\\ rarely\\ manifest\\.\\ the\\ incidence\\ increases\\ with\\ age\\ and\\ is\\ between\\ 4\\ and\\ 10\\%\\;\\ furthermore\\,\\ the\\ risk\\ of\\ rupture\\ of\\ aneurysms\\ \\<\\ 7\\ mm\\ is\\ low\\ in\\ patients\\ with\\ no\\ preceding\\ rupture\\.\\ procedures\\ of\\ choice\\ for\\ screening\\ for\\ cerebral\\ aneurysms\\ are\\ ct\\ angiography\\ and\\ mra\\.\\ however\\,\\ both\\ these\\ tests\\ carry\\ risks\\:\\ gadolinium\\ during\\ mri\\ has\\ a\\ strong\\ association\\ with\\ nephrogenic\\ systemic\\ fibrosis\\ in\\ pkd\\ patients\\ with\\ moderate\\/severe\\ disease\\,\\ especially\\ if\\ they\\ are\\ on\\ dialysis\\.\\ on\\ the\\ other\\ hand\\,\\ cerebral\\ angiography\\ is\\ associated\\ with\\ increased\\ risk\\ of\\ cerebral\\ bleed\\ or\\ stroke\\.\\(6\\)\\ hence\\,\\ due\\ to\\ the\\ low\\ incidence\\ and\\ risk\\ of\\ rupture\\ and\\ adverse\\ effects\\ associated\\ with\\ screening\\,\\ the\\ current\\ recommendation\\ is\\ to\\ screen\\ only\\ in\\ high\\-risk\\ patients\\ \\(including\\ those\\ with\\ family\\ history\\ of\\ aneurysm\\/stroke\\,\\ those\\ with\\ symptoms\\ such\\ as\\ new\\-onset\\ headache\\ or\\ neurologic\\ defect\\,\\(7\\)\\ \\ and\\ those\\ on\\ anticoagulant\\ therapy\\)\\,\\ and\\ perform\\ intermittent\\ follow\\-up\\ imaging\\ in\\ patients\\ with\\ found\\ aneurysms\\ until\\ the\\ stability\\ of\\ the\\ size\\ of\\ the\\ aneurysm\\(s\\)\\ has\\ been\\ determined\\.\\(6\\)\ \(0\)\
\-\ hepatic\\ cysts\\ are\\ common\\ in\\ patients\\ with\\ adpkd\\:\\ \\>80\\%\\ of\\ pts\\ with\\ adpkd\\ have\\ liver\\ cysts\\.7\\ the\\ prevalence\\ and\\ volume\\ of\\ liver\\ cysts\\ has\\ been\\ found\\ to\\ be\\ proportional\\ to\\ the\\ volume\\ of\\ the\\ kidneys\\.\\ however\\,\\ the\\ cysts\\ are\\ usually\\ asymptomatic\\,\\ albeit\\ rarely\\ cause\\ pain\\ and\\/or\\ infection\\.\\ \\(6\\)\ \(0\)\
\-\ other\\ manifestations\\ of\\ adpkd\\ include\\ cardiac\\ complications\\,\\ such\\ as\\ valvular\\ abnormalities\\ \\(especially\\ mild\\ mitral\\ valve\\ prolapsed\\ and\\ aortic\\ regurgitation\\)\\,\\ likely\\ due\\ to\\ the\\ collagen\\ and\\ extracellular\\ matrix\\ defects\\ associated\\ with\\ the\\ disease\\,\\ and\\ colonic\\ diverticula\\ and\\ abdominal\\ wall\\ and\\ inguinal\\ hernias\\.\\(6\\)\ \(0\)\
\-\ screening\ \(214\)\
\-\ screening\\ for\\ kidney\\ cysts\ \(0\)\
\-\ ultrasound\\ is\\ the\\ screening\\ test\\ of\\ choice\\ due\\ to\\ cost\\ and\\ safety\\ considerations\\ 1\\ and\\ can\\ detect\\ cysts\\ \\>\\ 1\\ cm\\.\\ mri\\ can\\ also\\ detect\\ presence\\ of\\ cysts\\ as\\ small\\ as\\ 3\\ mm\\,\\ appearing\\ as\\ \\‚\\Ä\\úblack\\ holes\\ interspersed\\ on\\ a\\ blanket\\ of\\ bright\\ parenchyma\\‚\\Ä\\ù\\ on\\ t\\¬\\¨1\\ weighted\\ imaging\\ and\\ as\\ bright\\ areas\\ on\\ t2\\ weighted\\ mri\\.\\(7\\)\ \(0\)\
\-\ ultrasound\\ criteria\\ for\\ the\\ diagnosis\\ of\\ pkd\\ in\\ patients\\ with\\ unknown\\ genotype\\ have\\ been\\ proposed\\.\\ diagnosis\\ of\\ pkd\\ can\\ be\\ made\\ if\\ three\\ or\\ more\\ renal\\ cysts\\ are\\ present\\ in\\ 15\\-39\\ yo\\ patients\\,\\ two\\ or\\ more\\ cysts\\ in\\ each\\ kidney\\ in\\ 40\\-59\\ yo\\ patients\\,\\ and\\ four\\ or\\ more\\ cysts\\ in\\ each\\ kidney\\ in\\ patients\\ over\\ 60\\ yo\\.\\ fewer\\ than\\ two\\ cysts\\ in\\ patients\\ over\\ 40\\ yo\\ who\\ are\\ at\\ risk\\ excludes\\ diagnosis\\ of\\ pkd\\.\\(8\\)\\ these\\ criteria\\ have\\ sensitivity\\ close\\ to\\ 100\\%\\ in\\ patients\\ \\&\\#8805\\;30\\ yo\\ and\\ for\\ younger\\ patients\\ with\\ mutation\\ of\\ pkd1\\ as\\ well\\ as\\ 67\\%\\ for\\ younger\\ patients\\ with\\ mutation\\ of\\ pkd2\\.\\ it\\ is\\ important\\ to\\ note\\ that\\ the\\ above\\ criteria\\ are\\ applicable\\ to\\ ultrasound\\ but\\ not\\ ct\\ or\\ mri\\,\\ as\\ these\\ latter\\ modalities\\ have\\ higher\\ sensitivity\\ than\\ does\\ ultrasound\\.\\(1\\)\\ \ \(0\)\
\-\ genetic\\ testing\\ is\\ possible\\ but\\ reserved\\ for\\ inconclusive\\ imaging\\ or\\ testing\\ of\\ a\\ younger\\ patient\\,\\ such\\ as\\ a\\ potential\\ living\\ related\\ kidney\\ donor\\.\\(1\\)\\ \ \(0\)\
\-\ screening\\ for\\ hepatic\\ cysts\ \(0\)\
\-\ different\\ imaging\\ modalities\\ are\\ used\\ to\\ detect\\ complications\\ of\\ liver\\ involvement\\ in\\ adpkd\\.\\ mri\\ detects\\ complicated\\ liver\\ cysts\\,\\ while\\ ct\\ scan\\ can\\ show\\ signs\\ of\\ infection\\,\\ including\\ \\‚\\Ä\\úfluid\\-debris\\ concentrations\\ within\\ cysts\\,\\ cyst\\ wall\\ thickening\\,\\ intracystic\\ gas\\ bubbles\\,\\ and\\ heterogeneous\\ or\\ increased\\ density\\,\\‚\\Ä\\ù\\ with\\ diagnosis\\ made\\ using\\ radionuclide\\ imaging\\ and\\ 18\\-f\\ fluorodoxyglucose\\ pet\\.\\(1\\)\\ \ \(0\)\
\-\ screening\\ for\\ brain\\ aneurysms\ \(1\)\
\-\ as\\ discussed\\ above\\,\\ screening\\ for\\ brain\\ aneurysms\\ is\\ only\\ done\\ in\\ the\\ select\\ cases\\ of\\ high\\-risk\\ patients\\.\ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ references\ \(24\)\
\-\ 1\\.\\	torres\\,\\ ve\\ et\\ al\\.\\ autosomal\\ dominant\\ polycystic\\ kidney\\ disease\\.\\ lancet\\ 2007\\;\\ 369\\:\\ 1287\\-301\\.\ \(0\)\
\-\ 2\\.\\	polycystic\\ kidney\\ disease\\.\\ torra\\,\\ r\\.\\ emedicine\\.\\ web\\ site\\:\\ http\\:\\/\\/emedicine\\.medscape\\.com\\/article\\/244907\\-overview\\.\\ accessed\\ on\\ 19\\ oct\\ 2009\\.\\ \ \(0\)\
\-\ 3\\.\\	kumar\\ et\\ al\\.\\ robbins\\ and\\ cotran\\ pathologic\\ basis\\ of\\ disease\\,\\ 7th\\ ed\\.\\ philadelphia\\,\\ elsevier\\ inc\\.\\,\\ 2005\\.\ \(0\)\
\-\ 4\\.\\	grantham\\ jj\\ et\\ al\\.\\ volume\\ progression\\ in\\ polycystic\\ kidney\\ disease\\.\\ n\\ eng\\ j\\ med\\ 2006\\;\\ 354\\:\\ 2122\\-2130\\.\\ \ \(0\)\
\-\ 5\\.\\	chapman\\ ab\\ et\\ al\\.\\ renal\\ manifestations\\ of\\ autosomal\\ dominant\\ polycystic\\ kidney\\ disease\\.\\ uptodate\\.\\ web\\ site\\:\\ www\\.uptodate\\.com\\.\\ accessed\\ on\\ 19\\ oct\\ 2009\\.\\ \ \(0\)\
\-\ 6\\.\\	bennett\\,\\ wm\\ and\\ rose\\,\\ bd\\.\\ extrarenal\\ manifestations\\ of\\ autosomal\\ dominant\\ polycystic\\ kidney\\ disease\\.\\ uptodate\\.\\ web\\ site\\:\\ www\\.uptodate\\.com\\.\\ accessed\\ on\\ 19\\ oct\\ 2009\\.\\ \ \(0\)\
\-\ 7\\.\\	grantham\\ jj\\.\\ autosomal\\ dominant\\ polycystic\\ kidney\\ disease\\.\\ n\\ eng\\ j\\ med\\ 2008\\;\\ 359\\:\\ 1477\\-85\\.\\ \ \(0\)\
\-\ 8\\.\\	pei\\ y\\ et\\ al\\.\\ unified\\ criteria\\ for\\ ultrasonographic\\ diagnosis\\ of\\ adpkd\\.\\ j\\ am\\ soc\\ nephrol\\ 2009\\;\\ 20\\:\\ 205\\-212\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ adpkd\\:\\ 0\\.29556103650099624\ \(0\)\
\-\ cysts\\:\\ 0\\.2767233124226363\ \(0\)\
\-\ kidney\\:\\ 0\\.2565525442838627\ \(0\)\
\-\ polycystic\\:\\ 0\\.1930606890702166\ \(0\)\
\-\ of\\:\\ 0\\.17469020374066835\ \(0\)\
\-\ aneurysms\\:\\ 0\\.1736187348083181\ \(0\)\
\-\ and\\:\\ 0\\.17188121213522828\ \(0\)\
\-\ renal\\:\\ 0\\.16423919107062826\ \(0\)\
\-\ patients\\:\\ 0\\.15978192801415672\ \(0\)\
\-\ screening\\:\\ 0\\.13184471616213828\ \(0\)\
\-\ pkd\\:\\ 0\\.12977841066652795\ \(0\)\
\-\ in\\:\\ 0\\.12617363132308534\ \(0\)\
\-\ manifestations\\:\\ 0\\.12473584524713155\ \(0\)\
\-\ as\\:\\ 0\\.12225491586238801\ \(0\)\
\-\ volume\\:\\ 0\\.10694470105853188\ \(0\)\
\-\ the\\:\\ 0\\.105251911650774\ \(0\)\
\-\ autosomal\\:\\ 0\\.10463057196740323\ \(0\)\
\-\ disease\\:\\ 0\\.10219315299462826\ \(0\)\
\-\ liver\\:\\ 0\\.09796821620125098\ \(0\)\
\-\ dominant\\:\\ 0\\.09492991127707472\ \(0\)\
\-\ uptodate\\:\\ 0\\.09442773473100148\ \(0\)\
\-\ 2009\\:\\ 0\\.08752082357547439\ \(0\)\
\-\ risk\\:\\ 0\\.08697604265531535\ \(0\)\
\-\ or\\:\\ 0\\.08469315622726067\ \(0\)\
\-\ is\\:\\ 0\\.08333926205539723\ \(0\)\
\-\ extrarenal\\:\\ 0\\.08254257548557457\ \(0\)\
\-\ cell\\:\\ 0\\.0812388786365984\ \(0\)\
\-\ al\\:\\ 0\\.08059942318027304\ \(0\)\
\-\ criteria\\:\\ 0\\.08047430228545664\ \(0\)\
\-\ et\\:\\ 0\\.07946304115812675\ \(0\)\
\-\ complications\\:\\ 0\\.07769135376838567\ \(0\)\
\-\ are\\:\\ 0\\.07698295945168142\ \(0\)\
\-\ to\\:\\ 0\\.07607863769100205\ \(0\)\
\-\ for\\:\\ 0\\.07378890363021269\ \(0\)\
\-\ with\\:\\ 0\\.07150687408463606\ \(0\)\
\-\ oct\\:\\ 0\\.07038524592404238\ \(0\)\
\-\ cerebral\\:\\ 0\\.07027785708653905\ \(0\)\
\-\ accessed\\:\\ 0\\.06880166103251349\ \(0\)\
\-\ growth\\:\\ 0\\.06691528365518155\ \(0\)\
\-\ detect\\:\\ 0\\.0656406176816058\ \(0\)\
\-\ web\\:\\ 0\\.0656406176816058\ \(0\)\
\-\ polycystin\\:\\ 0\\.06488920533326398\ \(0\)\
\-\ pkd1\\:\\ 0\\.06488920533326398\ \(0\)\
\-\ pkd2\\:\\ 0\\.06488920533326398\ \(0\)\
\-\ grantham\\:\\ 0\\.06488920533326398\ \(0\)\
\-\ nephrolithiasis\\:\\ 0\\.06387927965740708\ \(0\)\
\-\ younger\\:\\ 0\\.06364981664374596\ \(0\)\
\-\ yo\\:\\ 0\\.06337332072246203\ \(0\)\
\-\ mri\\:\\ 0\\.06248372634769896\ \(0\)\
\-\ eng\\:\\ 0\\.05995879449515684\ \(0\)\
\-\ been\\:\\ 0\\.059099499032624875\ \(0\)\
\-\ cyst\\:\\ 0\\.058516407510505845\ \(0\)\
\-\ proportional\\:\\ 0\\.058371556727033015\ \(0\)\
\-\ progression\\:\\ 0\\.055809568597517324\ \(0\)\
\-\ on\\:\\ 0\\.055145363972092534\ \(0\)\
\-\ jj\\:\\ 0\\.05502838365704972\ \(0\)\
\-\ possible\\:\\ 0\\.05498444802614443\ \(0\)\
\-\ associated\\:\\ 0\\.05346594966085152\ \(0\)\
\-\ imaging\\:\\ 0\\.05330961724156325\ \(0\)\
\-\ can\\:\\ 0\\.05323196341439056\ \(0\)\
\-\ that\\:\\ 0\\.05282485616046299\ \(0\)\
\-\ diagnosis\\:\\ 0\\.05258524857515664\ \(0\)\
\-\ found\\:\\ 0\\.05250851546946487\ \(0\)\
\-\ such\\:\\ 0\\.05220057793717929\ \(0\)\
\-\ those\\:\\ 0\\.05208046792585368\ \(0\)\
\-\ have\\:\\ 0\\.05067433490456206\ \(0\)\
\-\ ultrasound\\:\\ 0\\.05005555686802782\ \(0\)\
\-\ rupture\\:\\ 0\\.04920465616057924\ \(0\)\
\-\ site\\:\\ 0\\.04908804714308568\ \(0\)\
\-\ hepatic\\:\\ 0\\.04846852851509865\ \(0\)\
\-\ 19\\:\\ 0\\.04819839715256029\ \(0\)\
\-\ due\\:\\ 0\\.04664722140476864\ \(0\)\
\-\ hernias\\:\\ 0\\.04664451724117904\ \(0\)\
\-\ mutation\\:\\ 0\\.045626629597376914\ \(0\)\
\-\ uti\\:\\ 0\\.04516756198083545\ \(0\)\
\-\ more\\:\\ 0\\.04456068000593959\ \(0\)\
\-\ abdominal\\:\\ 0\\.044383735454527944\ \(0\)\
\-\ furthermore\\:\\ 0\\.04413487083686046\ \(0\)\
\-\ diverticula\\:\\ 0\\.04394517748148825\ \(0\)\
\-\ modalities\\:\\ 0\\.043404683702079526\ \(0\)\
\-\ treatments\\:\\ 0\\.04199308644458779\ \(0\)\
\-\ sensitivity\\:\\ 0\\.0411869705229235\ \(0\)\
\-\ inguinal\\:\\ 0\\.040937363183568526\ \(0\)\
\-\ matrix\\:\\ 0\\.040815769124081906\ \(0\)\
\-\ med\\:\\ 0\\.040815769124081906\ \(0\)\
\-\ emedicine\\:\\ 0\\.04034917045414695\ \(0\)\
\-\ mra\\:\\ 0\\.040126868634948076\ \(0\)\
\-\ genetic\\:\\ 0\\.04001826989549518\ \(0\)\
\-\ measured\\:\\ 0\\.04001826989549518\ \(0\)\
\-\ colonic\\:\\ 0\\.03959973275479967\ \(0\)\
\-\ choice\\:\\ 0\\.03847427286397239\ \(0\)\
\-\ each\\:\\ 0\\.03847427286397239\ \(0\)\
\-\ stroke\\:\\ 0\\.03773351494515995\ \(0\)\
\-\ angiography\\:\\ 0\\.037502800257723505\ \(0\)\
\-\ valve\\:\\ 0\\.03720637906501155\ \(0\)\
\-\ has\\:\\ 0\\.03706749652862144\ \(0\)\
\-\ wall\\:\\ 0\\.03702390261840177\ \(0\)\
\-\ bright\\:\\ 0\\.03699189811440231\ \(0\)\
\-\ infection\\:\\ 0\\.036765008348948976\ \(0\)\
\-\ testing\\:\\ 0\\.03644968682218415\ \(0\)\
\-\ carcinoma\\:\\ 0\\.03640572797667368\ \(0\)\
\-\ include\\:\\ 0\\.036213161949288676\ \(0\)\
\-\ rarely\\:\\ 0\\.03619333189724902\ \(0\)\
\-\ two\\:\\ 0\\.03614399075792231\ \(0\)\
\-\ defects\\:\\ 0\\.034980893443706466\ \(0\)\
\-\ kidneys\\:\\ 0\\.0349280078523861\ \(0\)\
\-\ incidence\\:\\ 0\\.0349280078523861\ \(0\)\
\-\ than\\:\\ 0\\.034501724444568775\ \(0\)\
\-\ important\\:\\ 0\\.03437082724218024\ \(0\)\
\-\ these\\:\\ 0\\.034369545782232454\ \(0\)\
\-\ over\\:\\ 0\\.033842719762447626\ \(0\)\
\-\ development\\:\\ 0\\.033543862025865255\ \(0\)\
\-\ total\\:\\ 0\\.033246555736497437\ \(0\)\
\-\ be\\:\\ 0\\.032919791300544586\ \(0\)\
\-\ increased\\:\\ 0\\.032912026325849046\ \(0\)\
\-\ function\\:\\ 0\\.03284229472556288\ \(0\)\
\-\ arbs\\:\\ 0\\.03244460266663199\ \(0\)\
\-\ echinococcosis\\:\\ 0\\.03244460266663199\ \(0\)\
\-\ iothalamate\\:\\ 0\\.03244460266663199\ \(0\)\
\-\ blanket\\:\\ 0\\.03244460266663199\ \(0\)\
\-\ 8805\\:\\ 0\\.03244460266663199\ \(0\)\
\-\ fluorodoxyglucose\\:\\ 0\\.03244460266663199\ \(0\)\
\-\ torres\\:\\ 0\\.03244460266663199\ \(0\)\
\-\ ve\\:\\ 0\\.03244460266663199\ \(0\)\
\-\ torra\\:\\ 0\\.03244460266663199\ \(0\)\
\-\ pei\\:\\ 0\\.03244460266663199\ \(0\)\
\-\ unified\\:\\ 0\\.03244460266663199\ \(0\)\
\-\ especially\\:\\ 0\\.032096787990264615\ \(0\)\
\-\ made\\:\\ 0\\.03129446469959698\ \(0\)\
\-\ enlargement\\:\\ 0\\.031107267599476095\ \(0\)\
\-\ interactions\\:\\ 0\\.03100254993991107\ \(0\)\
\-\ prolapsed\\:\\ 0\\.03100254993991107\ \(0\)\
\-\ genotype\\:\\ 0\\.03100254993991107\ \(0\)\
\-\ chapman\\:\\ 0\\.03100254993991107\ \(0\)\
\-\ ct\\:\\ 0\\.03089501784851264\ \(0\)\
\-\ aneurysm\\:\\ 0\\.03089492110627692\ \(0\)\
\-\ failure\\:\\ 0\\.030805820827280558\ \(0\)\
\-\ rate\\:\\ 0\\.030747034713626258\ \(0\)\
\-\ weighted\\:\\ 0\\.030266046958733812\ \(0\)\
\-\ cardiac\\:\\ 0\\.030130555638039087\ \(0\)\
\-\ but\\:\\ 0\\.03009704065587505\ \(0\)\
\-\ filtration\\:\\ 0\\.02997939724757842\ \(0\)\
\-\ holes\\:\\ 0\\.02997939724757842\ \(0\)\
\-\ detects\\:\\ 0\\.02997939724757842\ \(0\)\
\-\ 369\\:\\ 0\\.02997939724757842\ \(0\)\
\-\ cotran\\:\\ 0\\.02997939724757842\ \(0\)\
\-\ 354\\:\\ 0\\.02997939724757842\ \(0\)\
\-\ nephrol\\:\\ 0\\.02997939724757842\ \(0\)\
\-\ 40\\:\\ 0\\.02984125930861528\ \(0\)\
\-\ defect\\:\\ 0\\.029764360405431352\ \(0\)\
\-\ above\\:\\ 0\\.029271909184293576\ \(0\)\
\-\ interspersed\\:\\ 0\\.029185778363516508\ \(0\)\
\-\ kumar\\:\\ 0\\.029185778363516508\ \(0\)\
\-\ rose\\:\\ 0\\.029185778363516508\ \(0\)\
\-\ 359\\:\\ 0\\.029185778363516508\ \(0\)\
\-\ mm\\:\\ 0\\.029037905211588947\ \(0\)\
\-\ including\\:\\ 0\\.029037905211588947\ \(0\)\
\-\ antihypertensive\\:\\ 0\\.028537344520857506\ \(0\)\
\-\ preserving\\:\\ 0\\.028537344520857506\ \(0\)\
\-\ predictor\\:\\ 0\\.028537344520857506\ \(0\)\
\-\ glomerular\\:\\ 0\\.028537344520857506\ \(0\)\
\-\ robbins\\:\\ 0\\.028537344520857506\ \(0\)\
\-\ soc\\:\\ 0\\.028537344520857506\ \(0\)\
\-\ does\\:\\ 0\\.028050776877409016\ \(0\)\
\-\ concentrating\\:\\ 0\\.02798910151862245\ \(0\)\
\-\ intracystic\\:\\ 0\\.02798910151862245\ \(0\)\
\-\ lancet\\:\\ 0\\.02798910151862245\ \(0\)\
\-\ bd\\:\\ 0\\.02798910151862245\ \(0\)\
\-\ genes\\:\\ 0\\.02751419182852486\ \(0\)\
\-\ albeit\\:\\ 0\\.02751419182852486\ \(0\)\
\-\ extracellular\\:\\ 0\\.02751419182852486\ \(0\)\
\-\ excludes\\:\\ 0\\.02751419182852486\ \(0\)\
\-\ select\\:\\ 0\\.02751419182852486\ \(0\)\
\-\ size\\:\\ 0\\.027473724446686974\ \(0\)\
\-\ three\\:\\ 0\\.027237508537579808\ \(0\)\
\-\ nephrogenic\\:\\ 0\\.027095291794136583\ \(0\)\
\-\ study\\:\\ 0\\.0270609962726399\ \(0\)\
\-\ declining\\:\\ 0\\.026720572944462943\ \(0\)\
\-\ preceding\\:\\ 0\\.026720572944462943\ \(0\)\
\-\ fewer\\:\\ 0\\.026720572944462943\ \(0\)\
\-\ concentrations\\:\\ 0\\.026720572944462943\ \(0\)\
\-\ bennett\\:\\ 0\\.026720572944462943\ \(0\)\
\-\ 1500\\:\\ 0\\.026381598512575644\ \(0\)\
\-\ donor\\:\\ 0\\.026381598512575644\ \(0\)\
\-\ ultrasonographic\\:\\ 0\\.026381598512575644\ \(0\)\
\-\ between\\:\\ 0\\.026364053861489843\ \(0\)\
\-\ safety\\:\\ 0\\.026072139101803938\ \(0\)\
\-\ inhibitors\\:\\ 0\\.025787464039643087\ \(0\)\
\-\ nephroma\\:\\ 0\\.025787464039643087\ \(0\)\
\-\ proteinuria\\:\\ 0\\.025787464039643087\ \(0\)\
\-\ carry\\:\\ 0\\.025787464039643087\ \(0\)\
\-\ anticoagulant\\:\\ 0\\.025787464039643087\ \(0\)\
\-\ cost\\:\\ 0\\.025787464039643087\ \(0\)\
\-\ inconclusive\\:\\ 0\\.025787464039643087\ \(0\)\
\-\ only\\:\\ 0\\.025349328288984816\ \(0\)\
\-\ brain\\:\\ 0\\.025294717047481298\ \(0\)\
\-\ manifests\\:\\ 0\\.02527852021774202\ \(0\)\
\-\ adverse\\:\\ 0\\.02527852021774202\ \(0\)\
\-\ slowing\\:\\ 0\\.025048986409471292\ \(0\)\
\-\ latter\\:\\ 0\\.025048986409471292\ \(0\)\
\-\ radionuclide\\:\\ 0\\.024833372539255136\ \(0\)\
\-\ elsevier\\:\\ 0\\.024833372539255136\ \(0\)\
\-\ multilocular\\:\\ 0\\.02463008637508302\ \(0\)\
\-\ clearance\\:\\ 0\\.02463008637508302\ \(0\)\
\-\ recommendation\\:\\ 0\\.02463008637508302\ \(0\)\
\-\ valvular\\:\\ 0\\.02463008637508302\ \(0\)\
\-\ ace\\:\\ 0\\.024437794159797688\ \(0\)\
\-\ pts\\:\\ 0\\.024437794159797688\ \(0\)\
\-\ manifest\\:\\ 0\\.024255367525409376\ \(0\)\
\-\ bubbles\\:\\ 0\\.024255367525409376\ \(0\)\
\-\ likely\\:\\ 0\\.024246970984746204\ \(0\)\
\-\ 7th\\:\\ 0\\.024081843372847963\ \(0\)\
\-\ not\\:\\ 0\\.024027417939808577\ \(0\)\
\-\ however\\:\\ 0\\.02401600656223501\ \(0\)\
\-\ volumes\\:\\ 0\\.02375829863818926\ \(0\)\
\-\ reserved\\:\\ 0\\.02360693368275037\ \(0\)\
\-\ living\\:\\ 0\\.02360693368275037\ \(0\)\
\-\ if\\:\\ 0\\.023575427415655388\ \(0\)\
\-\ measure\\:\\ 0\\.02346174864134746\ \(0\)\
\-\ proposed\\:\\ 0\\.02346174864134746\ \(0\)\
\-\ applicable\\:\\ 0\\.02346174864134746\ \(0\)\
\-\ ab\\:\\ 0\\.02346174864134746\ \(0\)\
\-\ sizes\\:\\ 0\\.02332225862058952\ \(0\)\
\-\ hence\\:\\ 0\\.02332225862058952\ \(0\)\
\-\ therapy\\:\\ 0\\.0233133093547972\ \(0\)\
\-\ low\\:\\ 0\\.02328249452278196\ \(0\)\
\-\ feature\\:\\ 0\\.0231880336483621\ \(0\)\
\-\ risks\\:\\ 0\\.023058690680515317\ \(0\)\
\-\ at\\:\\ 0\\.022988872297154544\ \(0\)\
\-\ serious\\:\\ 0\\.02293388701083783\ \(0\)\
\-\ wm\\:\\ 0\\.02269669649426465\ \(0\)\
\-\ identification\\:\\ 0\\.022474340366801154\ \(0\)\
\-\ von\\:\\ 0\\.022474340366801154\ \(0\)\
\-\ dialysis\\:\\ 0\\.022474340366801154\ \(0\)\
\-\ mean\\:\\ 0\\.02236816712020157\ \(0\)\
\-\ prevalence\\:\\ 0\\.022164880956029455\ \(0\)\
\-\ regurgitation\\:\\ 0\\.022164880956029455\ \(0\)\
\-\ mitral\\:\\ 0\\.02206743541843023\ \(0\)\
\-\ ability\\:\\ 0\\.021972588740744124\ \(0\)\
\-\ bilateral\\:\\ 0\\.021806820552051076\ \(0\)\
\-\ epithelial\\:\\ 0\\.02179016210635581\ \(0\)\
\-\ pain\\:\\ 0\\.021779160210975763\ \(0\)\
\-\ basis\\:\\ 0\\.021702341851039763\ \(0\)\
\-\ baseline\\:\\ 0\\.02145118767446851\ \(0\)\
\-\ varying\\:\\ 0\\.021293093219135695\ \(0\)\
\-\ increases\\:\\ 0\\.021293093219135695\ \(0\)\
\-\ strong\\:\\ 0\\.021141728263696806\ \(0\)\
\-\ other\\:\\ 0\\.02107155649010952\ \(0\)\
\-\ effects\\:\\ 0\\.021068394951559342\ \(0\)\
\-\ target\\:\\ 0\\.020996543222293895\ \(0\)\
\-\ considerations\\:\\ 0\\.020996543222293895\ \(0\)\
\-\ small\\:\\ 0\\.0209302570125962\ \(0\)\
\-\ screen\\:\\ 0\\.020926114393480647\ \(0\)\
\-\ perform\\:\\ 0\\.020926114393480647\ \(0\)\
\-\ hereditary\\:\\ 0\\.02085705320153595\ \(0\)\
\-\ present\\:\\ 0\\.02082065423908621\ \(0\)\
\-\ bleed\\:\\ 0\\.02078930754118859\ \(0\)\
\-\ black\\:\\ 0\\.02078930754118859\ \(0\)\
\-\ 2008\\:\\ 0\\.020722828229308533\ \(0\)\
\-\ collagen\\:\\ 0\\.02059348526146175\ \(0\)\
\-\ philadelphia\\:\\ 0\\.020530536014023205\ \(0\)\
\-\ stability\\:\\ 0\\.020468681591784263\ \(0\)\
\-\ tuberous\\:\\ 0\\.020231491075211085\ \(0\)\
\-\ correlation\\:\\ 0\\.020231491075211085\ \(0\)\
\-\ torsion\\:\\ 0\\.020231491075211085\ \(0\)\
\-\ 2006\\:\\ 0\\.020231491075211085\ \(0\)\
\-\ directly\\:\\ 0\\.020174585227073476\ \(0\)\
\-\ discussed\\:\\ 0\\.02011857557136416\ \(0\)\
\-\ 2007\\:\\ 0\\.020063434317474038\ \(0\)\
\-\ 67\\:\\ 0\\.019955652140906797\ \(0\)\
\-\ procedures\\:\\ 0\\.019902961701148\ \(0\)\
\-\ protocol\\:\\ 0\\.019799866377399836\ \(0\)\
\-\ no\\:\\ 0\\.019792081349640164\ \(0\)\
\-\ every\\:\\ 0\\.019650619040143688\ \(0\)\
\-\ slow\\:\\ 0\\.019554490495572972\ \(0\)\
\-\ tests\\:\\ 0\\.019415000474815036\ \(0\)\
\-\ determined\\:\\ 0\\.019324956687302244\ \(0\)\
\-\ frequency\\:\\ 0\\.019280775502587614\ \(0\)\
\-\ 2005\\:\\ 0\\.019280775502587614\ \(0\)\
\-\ complicated\\:\\ 0\\.019237136431986195\ \(0\)\
\-\ population\\:\\ 0\\.019194026332848953\ \(0\)\
\-\ am\\:\\ 0\\.01915143253474083\ \(0\)\
\-\ hypertrophy\\:\\ 0\\.019109342817086088\ \(0\)\
\-\ pet\\:\\ 0\\.018789438348490162\ \(0\)\
\-\ different\\:\\ 0\\.018567082221026668\ \(0\)\
\-\ stone\\:\\ 0\\.018531337803240327\ \(0\)\
\-\ destruction\\:\\ 0\\.018495949057201155\ \(0\)\
\-\ complication\\:\\ 0\\.018426210751568962\ \(0\)\
\-\ higher\\:\\ 0\\.018426210751568962\ \(0\)\
\-\ ml\\:\\ 0\\.018357813650678914\ \(0\)\
\-\ close\\:\\ 0\\.018357813650678914\ \(0\)\
\-\ association\\:\\ 0\\.01825762281025497\ \(0\)\
\-\ potential\\:\\ 0\\.018128279842408185\ \(0\)\
\-\ systemic\\:\\ 0\\.018003476172730695\ \(0\)\
\-\ 44\\:\\ 0\\.017942679142987385\ \(0\)\
\-\ hematuria\\:\\ 0\\.017942679142987385\ \(0\)\
\-\ flank\\:\\ 0\\.017795083705265273\ \(0\)\
\-\ current\\:\\ 0\\.017766285656157517\ \(0\)\
\-\ gas\\:\\ 0\\.017766285656157517\ \(0\)\
\-\ period\\:\\ 0\\.01773771891917841\ \(0\)\
\-\ major\\:\\ 0\\.01773771891917841\ \(0\)\
\-\ tubular\\:\\ 0\\.017625692661400093\ \(0\)\
\-\ though\\:\\ 0\\.017625692661400093\ \(0\)\
\-\ thought\\:\\ 0\\.01751708759273458\ \(0\)\
\-\ evaluated\\:\\ 0\\.01733466095834627\ \(0\)\
\-\ by\\:\\ 0\\.01723074974627188\ \(0\)\
\-\ disorder\\:\\ 0\\.017161136805784856\ \(0\)\
\-\ numerous\\:\\ 0\\.0171370245803231\ \(0\)\
\-\ ventricular\\:\\ 0\\.01706565349699836\ \(0\)\
\-\ fibrosis\\:\\ 0\\.01699568652645897\ \(0\)\
\-\ gadolinium\\:\\ 0\\.016904488205700254\ \(0\)\
\-\ until\\:\\ 0\\.016882049395414104\ \(0\)\
\-\ using\\:\\ 0\\.016686227115687263\ \(0\)\
\-\ 100\\:\\ 0\\.01664413739803252\ \(0\)\
\-\ pathologic\\:\\ 0\\.016623277868248718\ \(0\)\
\-\ intermittent\\:\\ 0\\.016581922290266893\ \(0\)\
\-\ test\\:\\ 0\\.016500626416266463\ \(0\)\
\-\ parenchyma\\:\\ 0\\.016480589520267284\ \(0\)\
\-\ four\\:\\ 0\\.016440851233860403\ \(0\)\
\-\ general\\:\\ 0\\.01628619470980819\ \(0\)\
\-\ involved\\:\\ 0\\.016267327081298993\ \(0\)\
\-\ ed\\:\\ 0\\.016229889476319113\ \(0\)\
\-\ neurologic\\:\\ 0\\.016211317425589674\ \(0\)\
\-\ appearing\\:\\ 0\\.016211317425589674\ \(0\)\
\-\ references\\:\\ 0\\.01617446176279106\ \(0\)\
\-\ us\\:\\ 0\\.01613798411345221\ \(0\)\
\-\ done\\:\\ 0\\.01613798411345221\ \(0\)\
\-\ same\\:\\ 0\\.016048393995132307\ \(0\)\
\-\ occurs\\:\\ 0\\.015995703555373515\ \(0\)\
\-\ family\\:\\ 0\\.01596100533251539\ \(0\)\
\-\ hand\\:\\ 0\\.015858896703081462\ \(0\)\
\-\ 80\\:\\ 0\\.01582550171938517\ \(0\)\
\-\ includes\\:\\ 0\\.015775989927201542\ \(0\)\
\-\ aortic\\:\\ 0\\.015678987378907598\ \(0\)\
\-\ progressive\\:\\ 0\\.015538270753677134\ \(0\)\
\-\ hypertension\\:\\ 0\\.015522973785437853\ \(0\)\
\-\ pressure\\:\\ 0\\.01544746055313846\ \(0\)\
\-\ related\\:\\ 0\\.015417698541527759\ \(0\)\
\-\ unknown\\:\\ 0\\.015373517356813129\ \(0\)\
\-\ note\\:\\ 0\\.015272513500124846\ \(0\)\
\-\ result\\:\\ 0\\.01518816473325703\ \(0\)\
\-\ used\\:\\ 0\\.01518816473325703\ \(0\)\
\-\ 60\\:\\ 0\\.015174299064104547\ \(0\)\
\-\ http\\:\\ 0\\.014998798507139486\ \(0\)\
\-\ greater\\:\\ 0\\.014946495511101629\ \(0\)\
\-\ occur\\:\\ 0\\.01492062965430764\ \(0\)\
\-\ calcifications\\:\\ 0\\.014806506291854156\ \(0\)\
\-\ abnormality\\:\\ 0\\.014756936992824708\ \(0\)\
\-\ abnormalities\\:\\ 0\\.014695931386731288\ \(0\)\
\-\ involvement\\:\\ 0\\.014683854839871903\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.014683854839871903\ \(0\)\
\-\ presence\\:\\ 0\\.014576972483583426\ \(0\)\
\-\ they\\:\\ 0\\.014496007109219226\ \(0\)\
\-\ defined\\:\\ 0\\.01447320870017107\ \(0\)\
\-\ sclerosis\\:\\ 0\\.014450555504904428\ \(0\)\
\-\ signs\\:\\ 0\\.014178931978978954\ \(0\)\
\-\ headache\\:\\ 0\\.013985538838245168\ \(0\)\
\-\ 30\\:\\ 0\\.013839957547091653\ \(0\)\
\-\ elevated\\:\\ 0\\.013830460773403925\ \(0\)\
\-\ cause\\:\\ 0\\.01382098929075462\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.01381154296479536\ \(0\)\
\-\ thickening\\:\\ 0\\.013802121662245426\ \(0\)\
\-\ areas\\:\\ 0\\.013774006578023653\ \(0\)\
\-\ available\\:\\ 0\\.01376468405726555\ \(0\)\
\-\ fever\\:\\ 0\\.013755385909138539\ \(0\)\
\-\ recent\\:\\ 0\\.013736862223343487\ \(0\)\
\-\ cases\\:\\ 0\\.013645663902584771\ \(0\)\
\-\ unremarkable\\:\\ 0\\.013600926965133197\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.013583188576078745\ \(0\)\
\-\ bilaterally\\:\\ 0\\.01353049813631995\ \(0\)\
\-\ density\\:\\ 0\\.013452897829510074\ \(0\)\
\-\ while\\:\\ 0\\.013111598101931677\ \(0\)\
\-\ 20\\:\\ 0\\.013088428380684483\ \(0\)\
\-\ show\\:\\ 0\\.012879159810336728\ \(0\)\
\-\ during\\:\\ 0\\.012850244694701652\ \(0\)\
\-\ usually\\:\\ 0\\.012771919335032104\ \(0\)\
\-\ age\\:\\ 0\\.012736879252258033\ \(0\)\
\-\ years\\:\\ 0\\.012436147550486698\ \(0\)\
\-\ syndrome\\:\\ 0\\.012230725967677724\ \(0\)\
\-\ cystic\\:\\ 0\\.012218649420818337\ \(0\)\
\-\ head\\:\\ 0\\.012100087120919596\ \(0\)\
\-\ lymphoma\\:\\ 0\\.01208263881299029\ \(0\)\
\-\ scan\\:\\ 0\\.012036524200865801\ \(0\)\
\-\ secondary\\:\\ 0\\.012025088372257743\ \(0\)\
\-\ 10\\:\\ 0\\.011863272778616462\ \(0\)\
\-\ blood\\:\\ 0\\.011782377563341533\ \(0\)\
\-\ t2\\:\\ 0\\.011672129130960312\ \(0\)\
\-\ cm\\:\\ 0\\.01165151145215976\ \(0\)\
\-\ one\\:\\ 0\\.011615715639663368\ \(0\)\
\-\ common\\:\\ 0\\.011505504184505853\ \(0\)\
\-\ mild\\:\\ 0\\.011500574814856257\ \(0\)\
\-\ who\\:\\ 0\\.011476029930460973\ \(0\)\
\-\ both\\:\\ 0\\.01131347159908032\ \(0\)\
\-\ symptoms\\:\\ 0\\.011100332800040455\ \(0\)\
\-\ none\\:\\ 0\\.01108715227983013\ \(0\)\
\-\ without\\:\\ 0\\.010701049691463809\ \(0\)\
\-\ tumor\\:\\ 0\\.010611694460019989\ \(0\)\
\-\ woman\\:\\ 0\\.010565950554396585\ \(0\)\
\-\ most\\:\\ 0\\.010558383445940143\ \(0\)\
\-\ it\\:\\ 0\\.010385039275648086\ \(0\)\
\-\ multiple\\:\\ 0\\.00992320262762944\ \(0\)\
\-\ contrast\\:\\ 0\\.009857425911491064\ \(0\)\
\-\ well\\:\\ 0\\.009823450893278381\ \(0\)\
\-\ treatment\\:\\ 0\\.009664153798243112\ \(0\)\
\-\ also\\:\\ 0\\.009542797862063938\ \(0\)\
\-\ within\\:\\ 0\\.00934393329111383\ \(0\)\
\-\ which\\:\\ 0\\.009225062751174904\ \(0\)\
\-\ from\\:\\ 0\\.008057452506810552\ \(0\)\
\-\ history\\:\\ 0\\.007751112594206426\ \(0\)\
\-\ left\\:\\ 0\\.006920609734441574\ \(0\)\
\-\ patient\\:\\ 0\\.0065986016083755825\ \(0\)\
